Evidence map›Paper›PMID 31719864›Full record

ArticleCellular and molecular bioengineering2017

Anti-HER2 VHH Targeted Magnetoliposome for Intelligent Magnetic Resonance Imaging of Breast Cancer Cells.

Sepideh Khaleghi, Fatemeh Rahbarizadeh, Davoud Ahmadvand, Hamid Reza Madaah Hosseini

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular bioengineering, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Nanobodies asRSC chemical biology · 2021
    Review
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Sepideh Khaleghi1Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, P.O. BOX. 14115-331, Tehran, Iran.
Fatemeh Rahbarizadeh1Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, P.O. BOX. 14115-331, Tehran, Iran.
Davoud Ahmadvand2School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Hamid Reza Madaah Hosseini3Materials Science and Engineering Department, Sharif University of Technology, Azadi Avenue, P.O. BOX. 11155-9466, Tehran, Iran.
Tarbiat Modares University · IRIran University of Medical Sciences · IRSharif University of Technology · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The combination of liposomes with magnetic nanoparticles, because of their strong effect on T2 relaxation can open new ways in the innovative cancer therapy and diagnosis. In order to design an intelligent contrast agent in MRI, we chose anti-HER2 nanobody the smallest fully functional antigen-binding fragments evolved from the variable domain, the VHH, of a camel heavy chain-only antibody. These targeted magnetoliposomes bind to the HER2 antigen which is highly expressed on breast and ovarian cancer cells so reducing the side effects as well as increasing image contrast and effectiveness. Cellular iron uptake analysis and

Indexed as

Breast cancerMagnetoliposomeMolecular imagingSpecific cell targetingVHH

Identifiers

PMID31719864
PMCPMC6816672
OpenAlexW2594285109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.